✦ LIBER ✦

Agalsidase alfa in pediatric patients with Fabry disease: A 7-year open-label study

✍ Scribed by Schiffmann, Raphael; Pastores, Gregory; Peter, Chang; Rick, Martin; Anna, Wijatyk

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety of agalsidase alfa in patients wi

✍ U Ramaswami; R Parini; C Kampmann; M Beck 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB

116. Safety of agalsidase alfa in Fabry

✍ Uma Ramaswami; Rossella Parini; Michael Beck 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Safety and effect of open-label agalsida

✍ Pano, Arian; Goker-Alpan, Ozlem; Longo, Nicola; McDonald, Marie; Shankar, Suma; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 52 KB

HGT-REP-059 treatment protocol: effect a

✍ Goker-Alpan, Ozlem; Nedd, Khan; Shankar, Suma; Lien, Y. Howard; Weinreb, Neal; W 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 47 KB

One-year experience with agalsidase alfa

✍ C Spisni; R Di Vito; A Stingone; S Stuard; B D'angelo; L Caravelli; M Mascitti 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB

Hearing improvement in patients with Fab

✍ D Hajioff; S Goodwin; R Quiney; J Zuckerman; KD MacDermot; A Mehta 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB